FAS Wealth Partners’s GSK GSK Stock Holding History

FAS Wealth Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,683	Closed	-$203K	–	530
2026 Q1	$203K	Buy	+3,683	New	+$200K	0.01%	339
2022 Q3	–	Sell	-6,005	Closed	-$327K	–	414
2022 Q2	$327K	Buy	6,005 +184	+3%	+$10.2K	0.03%	225
2022 Q1	$317K	Buy	5,821 +53	+0.9%	+$2.88K	0.03%	229
2021 Q4	$318K	Sell	5,768 -14,047	-71%	-$731K	0.03%	241
2021 Q3	$946K	Sell	19,815 -286	-1%	-$14.4K	0.09%	131
2021 Q2	$1M	Buy	20,101 +299	+2%	+$14.4K	0.09%	128
2021 Q1	$883K	Sell	19,802 -454	-2%	-$20.6K	0.09%	133
2020 Q4	$932K	Buy	20,256 +616	+3%	+$28.3K	0.11%	121
2020 Q3	$924K	Buy	19,640 +670	+4%	+$33.6K	0.13%	118
2020 Q2	$967K	Sell	18,970 -4	-0%	-$205	0.14%	106
2020 Q1	$899K	Buy	18,974 +4,555	+32%	+$243K	0.16%	100
2019 Q4	$847K	Buy	14,419 +123	+0.9%	+$6.84K	0.14%	105
2019 Q3	$763K	Buy	14,296 +565	+4%	+$29.1K	0.14%	104
2019 Q2	$687K	Buy	13,731 +397	+3%	+$19.9K	0.13%	114
2019 Q1	$697K	Buy	13,334 +129	+1%	+$6.45K	0.14%	109
2018 Q4	$631K	Buy	13,205 +106	+0.8%	+$5.22K	0.14%	107
2018 Q3	$658K	Buy	13,099 +123	+0.9%	+$6.25K	0.15%	88
2018 Q2	$654K	Buy	12,976 +48	+0.4%	+$2.42K	0.18%	85
2018 Q1	$631K	Buy	12,928 +136	+1%	+$6.33K	0.18%	88
2017 Q4	$567K	Sell	12,792 -792	-6%	-$36.6K	0.15%	100
2017 Q3	$689K	Buy	13,584 +1,311	+11%	+$66.5K	0.19%	80
2017 Q2	$662K	Buy	12,273 +128	+1%	+$6.82K	0.2%	76
2017 Q1	$640K	Sell	12,145 -217	-2%	-$11K	0.2%	75
2016 Q4	$595K	Buy	12,362 +2,276	+23%	+$112K	0.18%	76
2016 Q3	$544K	Buy	10,086 +1,066	+12%	+$58.4K	0.18%	73
2016 Q2	$489K	Buy	9,020 +206	+2%	+$10.9K	0.18%	76
2016 Q1	$447K	Buy	8,814 +2,184	+33%	+$109K	0.23%	54
2015 Q4	$334K	Buy	6,630 +392	+6%	+$20K	0.17%	84
2015 Q3	$300K	Buy	6,238 +2,405	+63%	+$125K	0.17%	74
2015 Q2	$200K	Sell	3,833 -197	-5%	-$11.1K	0.1%	108
2015 Q1	$232K	Sell	4,030 -313	-7%	-$17.9K	0.12%	88
2014 Q4	$232K	Buy	4,343 +6	+0.1%	+$336	0.12%	82
2014 Q3	$249K	Sell	4,337 -197	-4%	-$12.1K	0.14%	74
2014 Q2	$303K	Sell	4,534 -492	-10%	-$33.3K	0.17%	64
2014 Q1	$336K	Buy	5,026 +3	+0.1%	+$203	0.23%	53
2013 Q4	$335K	Buy	+5,023	New	+$326K	0.2%	57

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FAS Wealth Partners's GSK Position: Q2 2026 in Review

FAS Wealth Partners sold out of GSK (GSK) in Q2 2026, closing a stake of 3,683 shares — an estimated $203K sold.

FAS Wealth Partners first reported a position in GSK in Q4 2013 and held it in 36 quarters. The position peaked at $1M in Q2 2021. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

FAS Wealth Partners reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
FAS Wealth Partners sold 3,683 GSK shares in Q2 2026, an estimated $203K.
FAS Wealth Partners first reported a position in GSK in Q4 2013 and held it in 36 quarters.
FAS Wealth Partners's GSK position peaked at $1M in Q2 2021.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.